These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6126364)

  • 1. Dihydroergotamine increases the bioavailability of orally administered etilefrine.
    Hengstmann JH; Hengstmann R; Schwonzen S; Dengler HJ
    Eur J Clin Pharmacol; 1982; 22(5):463-7. PubMed ID: 6126364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.
    Barthel W; Glusa E; Koth W
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):63-9. PubMed ID: 2881898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bioavailability of etilefrine from Thomasin and Thomasin sustained-release tablets].
    Haustein KO; Hüller G
    Pharmazie; 1985 Nov; 40(11):776-8. PubMed ID: 2869507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physiological disposition of etilefrine in man.
    Hengstmann JH; Weyand U; Dengler HJ
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):179-87. PubMed ID: 9300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of dihydroergotamine in man.
    Little PJ; Jennings GL; Skews H; Bobik A
    Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of etilefrin hydrochloride (not sustained-action) and etilefrin hydrochloride sustained-action pellets in a crossover trial in humans. Investigation of absorption time, absorption rate, blood levels and half-life].
    Donike M; Dell HD; Kamp R
    Arzneimittelforschung; 1978; 28(5):856-60. PubMed ID: 35175
    [No Abstract]   [Full Text] [Related]  

  • 7. [Interaction of dihydroergotamine and etilefrine-hydrochloride at capacitance vessels of the calf in man (author's transl)].
    Inoue H; Inoue K; Arndt JO
    Z Kardiol; 1980 Apr; 69(4):280-6. PubMed ID: 6109407
    [No Abstract]   [Full Text] [Related]  

  • 8. Dihydroergotamine decreases the blood content in the skeletal musculature but etilefrine hydrochloride in the splanchnic region in man.
    Arndt JO; Höck A; Inoue K
    Basic Res Cardiol; 1984; 79(2):244-52. PubMed ID: 6146305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dihydroergotamine and etilefrine on experimentally-induced postural hypotension in dogs.
    Yamazaki R; Tsuchida K; Otomo S
    J Pharmacobiodyn; 1990 Sep; 13(9):519-24. PubMed ID: 1707454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of etilefrine and dihydroergotamine on sympathetic nervous system activity when standing up (author's transl)].
    Kaden F; Mäurer W; Schömig A; Spohr U
    Dtsch Med Wochenschr; 1978 Sep; 103(39):1513-7. PubMed ID: 28936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic comparison of etilefrine to its prodrug, the stearic acid ester of etilefrine.
    Rominger KL; Hitzenberger G
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):150-7. PubMed ID: 6103881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins.
    Thulesius O; Gjöres JE; Berlin E
    Eur J Clin Pharmacol; 1979; 16(6):423-4. PubMed ID: 93544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.
    Bobik A; Jennings G; Skews H; Esler M; McLean A
    Clin Pharmacol Ther; 1981 Nov; 30(5):673-9. PubMed ID: 6794970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dihydergot plus - 12-hour action in orthostatic disturbance and hypotension].
    Schardt F; Mishra BR
    Ther Ggw; 1982 Jan; 121(1):26-36. PubMed ID: 6121387
    [No Abstract]   [Full Text] [Related]  

  • 15. [Double blind study of migraine therapy with etilefrine pivalate].
    Cruz A; Bühling M; Seibel K
    Arzneimittelforschung; 1985; 35(7):1086-9. PubMed ID: 2864937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abnormalities of hypotonic orthostatic regulation: cardiovascular effects of dihydroergotamine, etilefrine and their combination (author's transl)].
    Gemeinhardt S; Schardt F; Polzien P
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1095-9. PubMed ID: 6114845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hypotensive circulatory dysregulation with a combination of dihydroergotamine and etilefrine (author's transl)].
    Bracharz H; Polzien P
    MMW Munch Med Wochenschr; 1981 Jan; 123(5):177-80. PubMed ID: 6110188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic aspects of orthostatic dysfunction].
    Rieckert H
    Med Klin Prax; 1982 Feb; 77(5):48-52. PubMed ID: 6123069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
    Aylward M; Davies DE; Maddock J; Robinson PR; Jones M
    Cephalalgia; 1983 Aug; 3 Suppl 1():146-50. PubMed ID: 6616596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular effects of etilefrine.
    Coleman AJ; Leary WP; Asmal AC
    Eur J Clin Pharmacol; 1975; 8(1):41-5. PubMed ID: 9293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.